

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/534,953	03/24/2000	Teresa Leigh Barr	310.18	1956	
7590 02/25/2004			EXAM	EXAMINER	
Buskop Law Group PC			KIM, JEN	KIM, JENNIFER M	
Wendy K Buskop Suite 500			ART UNIT	PAPER NUMBER	
1717 St James Place			1617		
Houston, TX	77056	•	DATE MAILED: 02/25/2004	DATE MAILED: 02/25/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
	Office Action Summary	09/534,953	BARR ET AL.			
Office Action Summary		Examiner	Art Unit			
	The MAILING DATE of this communication app	Jennifer Kim	1617			
Period fo		ears on the cover sheet wi	iui uie correspondence address			
THE - Exte after - If the - If NO - Failu	MAILING DATE OF THIS COMMUNICATION. Insigns of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply of period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a ray within the statutory minimum of third will apply and will expire SIX (6) MON, cause the application to become AE	reply be timely filed by (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on 21 No	ovember 2003.				
, <u> </u>	This action is FINAL . 2b) ☐ This action is non-final.					
′—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims		•			
4)⊠	Claim(s) <u>1-35</u> is/are pending in the application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
_	Claim(s) is/are allowed.					
	Claim(s) <u>1-35</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)	Claim(s) are subject to restriction and/or	· election requirement.				
Applicati	ion Papers					
9)[]	The specification is objected to by the Examine	r.				
	The drawing(s) filed on is/are: a) acce		by the Examiner.			
	Applicant may not request that any objection to the					
	Replacement drawing sheet(s) including the correcti	on is required if the drawing	(s) is objected to. See 37 CFR 1.121(d).			
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached	Office Action or form PTO-152.			
Priority ι	ınder 35 U.S.C. § 119					
_	Acknowledgment is made of a claim for foreign All b) Some * c) None of: Certified copies of the priority documents Certified copies of the priority documents Copies of the certified copies of the prior	s have been received. s have been received in A	pplication No			
	application from the International Bureau		The second secon			
* S	See the attached detailed Office action for a list of	• • • • • • • • • • • • • • • • • • • •	received.			
Attachmen	t(s)					
	e of References Cited (PTO-892)	4) Interview S	ummary (PTO-413)			
	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date			
	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	5) Notice of in 6) Other:	formal Patent Application (PTO-152)			

Application/Control Number: 09/534,953

Art Unit: 1617

DETAILED ACTION

The amendment filed on November 21, 2003 have been received and entered into the application.

The rejection of claim 16 of record under 35 U.S.C. 112, second paragraph is hereby expressly withdrawn in view of Applicants' amendment.

The rejection of claims 1-5, 11-25, 30, 32, 34 and 35 of record under 35 U.S.C. 103(c) over LaHann et al of record in view of Ishiwatari et al. of record is hereby expressly withdrawn in view of Applicants' amendment.

The rejection of claims 6-10, 26, 28 and 33 of record under 35 U.S.C. 103(c) over LaHann et al. in view of Ishiwatari et al. and further in view of Fourman et al., all of record is hereby expressly withdrawn in view of Applicants' amendment.

Claims 1-35 of record rejected under Double Patenting is maintained for the reasons stated in the previous office action dated November 6, 2002, since Applicants' allegation that a terminal disclaimer of U.S.Patent No. 6,348,501B1) has been inserted to over come the rejection located in Attachment B appears missing. A telephone call was made to Mr. Hausler on February 20, 2004 to resolve the above issue, but unable to reach Mr. Hausler.

Claim Objections

Application/Control Number: 09/534,953

Art Unit: 1617

Claims 20 and 33 are objected to because of the following informalities: With regard to claim 20, it appears the term "menthyl" should be "menthyl lauryl". With regard to claim 33 it appears the term "polsorbitol" should be "polysorbitol". Appropriate correction is required.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-35 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 6348501B1, Holt et al. of record in view of Scivoletto (U.S.Patent No. 6248763B1) of record. Although the conflicting claims are not identical, they are not patentably distinct from each other because it encompasses same subject matter. The difference between the Patent No. 6348501 and Applicant's claimed invention is lack of niacin well known as nicotinic acid. However, to incorporate niacin or nicotinic acid into Holt et al's composition is obvious in view of Scivoletto who teach on the abstract, and column 2,

Application/Control Number: 09/534,953

Art Unit: 1617

lines 8-12, lines 18-20, teach nicotinic acid is highly beneficial when topically applied to treat skin condition such as pain and itching. Therefore, the skill artisan would have been motivated to modify the Holt's composition by incorporating niacin to achieve highly beneficial for relieving pain and itching skin conditions as taught by Scivoletto. The skill artisan would have been motivated to combine these references and make such modification because they are drawn to same technical fields (constituted with same active ingredient and well known additives (e.g. carriers, excipients)), and pertinent to the problem which applicant concerns about. MPEP 2141.01(a).

For these reasons the claimed subject matter is deemed to fail to patentably distinguish over the state of the art as represented by the cited references. The claims are therefore properly rejected under the nonstatutory double patenting rejection.

It is suggested to draw independent claims 1, 3, 26, 27, 29, 31 and 33 to "encapsulated capsaicin" in order to advance prosecution of instant Applicantion.

None of the claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

Art Unit: 1617

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Sreenivasan Padmanabhan Supervisory Examiner

Art Unit 1617

Jmk February 20, 2004

Business Center (EBC) at 866-217-9197 (toll-free).